Theravance Biopharma Inc. (NASDAQ:TBPH) went down by -6.73% from its latest closing price compared to the recent 1-year high of $22.74. The company’s stock price has collected -6.40% of loss in the last five trading sessions. Press Release reported on 08/23/21 that Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
Is It Worth Investing in Theravance Biopharma Inc. (NASDAQ :TBPH) Right Now?
Plus, the 36-month beta value for TBPH is at 0.85. Opinions of the stock are interesting as 5 analysts out of 9 who provided ratings for Theravance Biopharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $17.56. TBPH currently public float of 61.17M and currently shorts hold a 3.43% ratio of that float. Today, the average trading volume of TBPH was 903.42K shares.
TBPH’s Market Performance
TBPH stocks went down by -6.40% for the week, with a monthly drop of -40.53% and a quarterly performance of -55.36%, while its annual performance rate touched -55.65%. The volatility ratio for the week stands at 5.78% while the volatility levels for the past 30 days are set at 6.28% for Theravance Biopharma Inc.. The simple moving average for the period of the last 20 days is -19.84% for TBPH stocks with a simple moving average of -52.95% for the last 200 days.
Analysts’ Opinion of TBPH
Many brokerage firms have already submitted their reports for TBPH stocks, with Morgan Stanley repeating the rating for TBPH by listing it as a “Underweight.” The predicted price for TBPH in the upcoming period, according to Morgan Stanley is $14 based on the research report published on August 25th of the current year 2021.
Cowen, on the other hand, stated in their research note that they expect to see TBPH reach a price target of $14, previously predicting the price at $42. The rating they have provided for TBPH stocks is “Market Perform” according to the report published on August 24th, 2021.
Morgan Stanley gave a rating of “Overweight” to TBPH, setting the target price at $32 in the report published on October 14th of the previous year.
TBPH Trading at -33.86% from the 50-Day Moving Average
After a stumble in the market that brought TBPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.64% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 5.78%, as shares sank -40.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.05% lower at present.
During the last 5 trading sessions, TBPH fell by -6.40%, which changed the moving average for the period of 200-days by -52.43% in comparison to the 20-day moving average, which settled at $9.76. In addition, Theravance Biopharma Inc. saw -54.76% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TBPH starting from WORBOYS PHILIP D, who sale 8,829 shares at the price of $20.00 back on Mar 09. After this action, WORBOYS PHILIP D now owns 343,679 shares of Theravance Biopharma Inc., valued at $176,580 using the latest closing price.
GRAHAM RICHARD A, the SVP, Development of Theravance Biopharma Inc., sale 7,500 shares at $19.47 during a trade that took place back on Dec 14, which means that GRAHAM RICHARD A is holding 123,749 shares at $146,058 based on the most recent closing price.
Stock Fundamentals for TBPH
Current profitability levels for the company are sitting at:
- -414.37 for the present operating margin
The net margin for Theravance Biopharma Inc. stands at -386.90. The total capital return value is set at -90.34, while invested capital returns managed to touch -90.80. Equity return is now at value 85.30, with -59.20 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 20.75, with the company’s debt to enterprise value settled at 0.45. The receivables turnover for the company is 1.20 and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.18.